Nursing Guide to Managing Lorlatinib in ALK+ NSCLC: 7-Year CROWN Insights

With long-term data from the phase 3 CROWN study showing that lorlatinib (Lorbrena) can extend progression-free survival (PFS) beyond seven years in patients with ALK-positive non-small cell lung cancer (NSCLC), the focus of care is shifting from acute treatment to chronic disease management. For oncology nurses, this transition requires a proactive approach to side effect monitoring and patient counseling.

In an interview at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Tony SK Mok, MD, emphasized that the first 24 months are the most critical for nursing intervention. “Most of the toxicities actually occur within the first two years,” Mok explained. “I think that first two years is important, and to me, the best way to manage toxicity is dose reduction, not waiting for the toxins to become severe.”

The efficacy landscape

The survival data remains unprecedented. At the seven-year mark, the PFS rate for patients on lorlatinib was 55%, compared to 3% for those on crizotinib (Xalkori). Furthermore, the treatment provided significant central nervous system (CNS) protection, with a 92% intracranial time-to-progression rate and no new brain metastases reported after 30 months. Because lorlatinib was specifically developed to penetrate the blood-brain barrier, it has the potential to transform the disease into a manageable chronic condition.

Identifying subtle cognitive shifts

One of the most nuanced roles for the oncology nurse is the assessment of cognitive effects, which are often grade 1 or 2 but can impact quality of life. Mok noted in our interview that these changes are frequently first identified by those in closest contact with the patient.

“Patients may notice it, their memory’s a little bit off, they’re a little more clumsy,” Mok said. “Those can be picked up by the family and the nurses, so once that's the case, then oncologists should reduce the dose.”

Nurses should encourage family members to report even minor behavioral or processing changes early to facilitate these necessary dose adjustments, which do not appear to compromise long-term efficacy.

Proactive metabolic management

Weight gain and hyperlipidemia are common with lorlatinib. Mok stressed that nurses should begin counseling immediately upon treatment initiation.

He recommended that regular dietary monitoring and regular exercise has to be in place” to manage these metabolic shifts before they become severe. By providing these tools early, nurses can help patients navigate the first four years of treatment, after which many patients “continue to live a normal life” with manageable side effects.

The collective effort of care

The successful long-term use of lorlatinib depends on more than just the medication; it requires a collective effort between the oncology team, the patient, and their support system. As the primary point of contact, the oncology nurse’s ability to catch early toxins and provide lifestyle guidance is essential to ensuring patients reach the long-term recovery phase seen in the CROWN trial.

Reference

1. Mok TSK, Solomon BJ, Felip E, et al. Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study. Presented at: 2026 ASCO Annual Meeting; May 29-June 2, 2026; Chicago, IL. Abstract 8502.